IP Library Granted Patent US 12,190,010
Granted Patent B2
US 12,190,010 · App. 18/470,092 · Granted Jan 7, 2025

Continuous glucose monitor communication with multiple display devices

Inventors: Hari Hampapuram (Beaverton, OR); Eric Cohen (San Diego, CA); Brian Christopher Smith (San Marcos, CA); Jose Hector Hernandez-Rosas (San Diego, CA); Francis William Pascual (San Diego, CA); Michael Robert Mensinger (San Diego, CA); Shawn Larvenz (Ramona, CA)
Assignee: Dexcom, Inc.
G06F3/1423A61B5/0004A61B5/14532A61B5/742A61B5/7445G06F3/1454G09G5/003G16H40/63G16Z99/00H04W76/11H04W76/14G09G2358/00G09G2370/16G09G2380/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,190,010
App. No.
18/470,092
Granted
Jan 7, 2025
Kind
B2
Abstract

A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.

Claims (48)

1. An analyte sensor system, comprising:

an analyte sensor configured to generate an electrical current indicative of an analyte measurement;

a sensor electronics module, comprising:

a transceiver;

a memory comprising executable instructions;

a processor in data communication with the transceiver and memory and configured to execute the executable instructions in the memory to cause the analyte sensor system to:

establish, via the transceiver, a first wireless connection with a first medical device;

subsequent to establishing the first wireless connection, remove the first medical device from a list of authorized devices that are permitted to wirelessly communicate with the analyte sensor system;

authenticate a second medical device of the same type as the first medical device;

add the second medical device to the list of authorized devices; and

subsequent to the adding, establish, via the transceiver, a second wireless connection with the second medical device.

2. The analyte sensor system of claim 1 , wherein the processor being configured to cause the analyte sensor system to remove the first medical device from the list of authorized devices further comprises the processor being configured to cause the analyte sensor system to remove bonding information associated with the first medical device.

3. The analyte sensor system of claim 1 , wherein the list of authorized devices comprises at least one of a whitelist or a list of bonded devices.

4. The analyte sensor system of claim 1 , wherein the analyte monitoring system is a continuous analyte monitoring system.

5. The analyte sensor system of claim 1 , wherein the removal of the first medical device from the list of authorized devices is in response to a request.

6. The analyte sensor system of claim 5 , wherein the request is received from the first medical device.

7. The analyte sensor system of claim 5 , wherein the request to remove the first medical device is provided by a user through a user interface on a third device and received by the analyte monitoring system from the third device.

8. The analyte sensor system of claim 7 , wherein:

the processor is further configured to cause the analyte monitoring system to provide the list of authorized devices to the third device, and

the request to remove the first medical device through the user interface on the third device comprises a selection of the first medical device from the list of authorized devices for removal.

9. The analyte sensor system of claim 5 , wherein the removal of the first medical device from the list of authorized devices is performed automatically.

10. The analyte sensor system of claim 1 , wherein at a time of the removal of the first medical device, the first medical device has not communicated with the analyte monitoring system for at least one of a defined period of time or a connection interval.

11. The analyte sensor system of claim 1 , wherein bonding information associated with the first medical device is:

retrained after the first medical device is removed from the list of authorized devices, and

used for reconnection.

12. The analyte sensor system of claim 1 , wherein the type of the first medical device is a dedicated display device.

13. The analyte sensor system of claim 1 , wherein the type of the first medical device is a class III medical device.

14. A method of wireless communication for use by an analyte sensor system, comprising:

establishing a first wireless connection with a first medical device;

subsequent to establishing the first wireless connection, removing the first medical device from a list of authorized devices that are permitted to wirelessly communicate with the analyte sensor system;

authenticating a second medical device of the same type as the first medical device;

adding the second medical device to the list of authorized devices; and

subsequent to the adding, establishing a second wireless connection with the second medical device.

15. The method of claim 14 , wherein removing the first medical device from the list of authorized devices comprises removing bonding information associated with the first medical device.

16. The method of claim 14 , wherein the list of authorized devices comprises at least one of a whitelist or a list of bonded devices.

17. The method of claim 14 , wherein the analyte monitoring system is a continuous analyte monitoring system.

18. The method of claim 14 , wherein removing the first medical device from the list of authorized devices is in response to a request.

19. The method of claim 18 , further comprising:

receiving the request from the first medical device.

20. The method of claim 18 , wherein the request to remove the first medical device is provided by a user through a user interface on a third device and received by the analyte monitoring system from the third device.

21. The method of claim 20 , further comprising providing the list of authorized devices to the third device, and wherein the request to remove the first medical device being provided through the user interface on the third device comprises a selection of the first medical device from the list of authorized devices for removal.

22. The method of claim 18 , wherein the removing of the first medical device from the list of authorized devices is performed automatically.

23. The method of claim 14 , wherein at a time of the removing of the first medical device, the first medical device has not communicated with the analyte monitoring system for at least one of a defined period of time or a connection interval.

24. The method of claim 14 , wherein bonding information associated with the first medical device is:

retrained after the first medical device is removed from the list of authorized devices, and

used for reconnection.

25. The method of claim 14 , wherein the type of the first medical device is a dedicated display device.

26. The method of claim 15 , wherein the type of the first medical device is a class III medical device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2024
From: HAMPAPURAM, HARI; COHEN, ERIC; SMITH, BRIAN CHRISTOPHER; HERNANDEZ-ROSAS, JOSE HECTOR; PASCUAL, FRANCIS WILLIAM; MENSINGER, MICHAEL ROBERT; LARVENZ, SHAWN
To: DEXCOM, INC.
Reel/Frame 067497/0803 →
Continuity (6)
Continuation 17814215 · Jul 21, 2022
Continuation 16198651 · Nov 21, 2018
Continuation 15001756 · Jan 20, 2016
Continuation 15002155 · Jan 20, 2016
Provisional Application 62106150 · Jan 21, 2015
Related Publication 20240012602A1 · Jan 11, 2024
References Cited (57)
US 2A · Goulding · 1836 [cited by examiner]
US 6219669B1 · Haff · 2001 [cited by examiner]
US 7660422B2 · Mitchell et al. · 2010 [cited by applicant]
US 7928850B2 · Hayter et al. · 2011 [cited by applicant]
US 8407759B1 · Sotos · 2013 [cited by examiner]
US 8589690B2 · Kassai · 2013 [cited by examiner]
US 8644823B2 · Rozinov · 2014 [cited by examiner]
US 8686216B2 · Wattebled · 2014 [cited by examiner]
US 8803688B2 · Halff et al. · 2014 [cited by applicant]
US 8844007B2 · Vicente · 2014 [cited by examiner]
US 8854206B2 · Kai · 2014 [cited by examiner]
US 9094379B1 · Miller · 2015 [cited by examiner]
US 9143569B2 · Mensinger · 2015 [cited by examiner]
US 9241768B2 · Sandhu · 2016 [cited by examiner]
US 9386522B2 · San Vicente et al. · 2016 [cited by applicant]
US 9603024B2 · Wang et al. · 2017 [cited by applicant]
US 9825961B2 · Etter et al. · 2017 [cited by applicant]
US 9931036B2 · Miller et al. · 2018 [cited by applicant]
US 10007473B2 · Hampapuram · 2018 [cited by examiner]
US 10168974B2 · Hampapuram et al. · 2019 [cited by applicant]
US 10359983B2 · Hampapuram et al. · 2019 [cited by applicant]
US 20040078449A1 · Tanaka · 2004 [cited by examiner]
US 20040117858A1 · Boudreau · 2004 [cited by examiner]
US 20050235345A1 · Mitchell · 2005 [cited by examiner]
US 20060001551A1 · Kraft · 2006 [cited by examiner]
US 20080278331A1 · Hayter · 2008 [cited by examiner]
US 20080298375A1 · Agardh · 2008 [cited by examiner]
US 20090240120A1 · Mensinger · 2009 [cited by examiner]
US 20110163881A1 · Halff · 2011 [cited by examiner]
US 20120078071A1 · Bohm · 2012 [cited by examiner]
US 20130017791A1 · Wang · 2013 [cited by examiner]
US 20130078912A1 · San Vicente · 2013 [cited by examiner]
US 20130231711A1 · Kaib · 2013 [cited by examiner]
US 20140266776A1 · Miller · 2014 [cited by examiner]
US 20140313052A1 · Yarger · 2014 [cited by examiner]
US 20150123811A1 · Hernandez-Rosas · 2015 [cited by examiner]
US 20160034764A1 · Connor · 2016 [cited by examiner]
US 20160050212A1 · Etter · 2016 [cited by examiner]
US 20180027105A1 · Mandapaka · 2018 [cited by examiner]
US 20180110077A1 · Mandapaka · 2018 [cited by examiner]
US 20190095165A1 · Hampapuram et al. · 2019 [cited by applicant]
CA 2690742A1 · 2008 [cited by applicant]
CN 1885770A · 2006 [cited by applicant]
CN 102594987A · 2012 [cited by applicant]
CN 103930029A · 2014 [cited by applicant]
CN 104320161A · 2015 [cited by applicant]
JP 2009055428A · 2009 [cited by applicant]
JP 2010507928A · 2010 [cited by applicant]
JP 2012105100A · 2012 [cited by applicant]
JP 2013502978A · 2013 [cited by applicant]
JP 2013172259A · 2013 [cited by applicant]
KR 20140129759A · 2014 [cited by applicant]
WO 2013044153A1 · 2013 [cited by applicant]
WO 2014099012A1 · 2014 [cited by applicant]
WO 2014188827A1 · 2014 [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2016/014145 mailed on Aug. 3, 2017, 13 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2016/014145 mailed on Jun. 27, 2016, 17 pages. [cited by applicant]